RxSight, Inc. (RXST) Cash Flow Statement
RxSight, Inc. (RXST) generated -$22.7M of operating cash flow over the twelve months to 2026-06-30, spent $4.4M on capital expenditure and had free cash flow of -$27.2M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RXSTRxSight, Inc.Follow RXST — free
—
Price chart with a free account
- Market cap
- 208.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 9 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -44.7 | -58.9 | -41.6 | -16.9 | -15.5 | -22.7 | |
| Capital expenditure | 1.9 | 2.4 | 4.8 | 5.4 | 3.8 | -4.4 | |
| Free cash flow | -46.6 | -61.2 | -46.4 | -22.4 | -19.3 | -27.2 | |
| Stock-based compensation | 7.6 | 11.4 | 15.7 | 24.6 | 31.6 | — |
USD millions · SEC XBRL
RxSight, Inc. — questions
- What is RxSight, Inc.'s operating cash flow?
- -$22.7M over the twelve months to 2026-06-30.
- How much does RxSight, Inc. spend on capital expenditure?
- $4.4M over the twelve months to 2026-06-30.
- What is RxSight, Inc.'s free cash flow?
- -$27.2M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from RxSight, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.